Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.
Journal: Science translational medicine
•
Abstract
Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.
Subjects & Keywords
How to Cite this Article
deCamp AC, Juraska M, Li L, et al. (2026). "Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections.". Science translational medicine. https://doi.org/10.1126/scitranslmed.aec3480